RxDoctor Payments Data

Jeffrey Hick, MD

Procedural Dermatology · Manhattan Beach, CANPI 1972757359

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novartis at 28.4% of the total.

$3,485in general payments, 2019–2025

Across 192 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$989
  • Incyte Corporation$510
  • Johnson & Johnson$448
  • UCB, Inc.$309
  • Pfizer$222
  • Sun Pharmaceutical Industries Inc.$186
  • plus $821 from 15 others

What the payments were for

  • Food & beverage$3,28094%
  • Education$2056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,485 in reported general payments places this provider in the 60th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$897,198
Medicare patients
798
Services billed
9,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate72$5,276
Fluorouracil21$1,352
Halobetasol Propionate13$1,094
Ketoconazole73$860
Metronidazole13$749
Betamethasone Dipropionate18$664
Mupirocin101$649
Fluticasone Propionate31$568
Clindamycin Phosphate13$542
Doxycycline Hyclate22$480
Triamcinolone Acetonide54$443
Ciclopirox11$380
Hydrocortisone42$206
Cephalexin14$129
Terbinafine Hcl15$79

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Manhattan Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →